Publication | Open Access

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study

Allergen-specific ImmunotherapyAllergyAllergy MedicineImmunodeficienciesImmunologyOral ImmunotherapyAllergenPhase Iib StudyHumoral ImmunityImmunotherapeuticsImmune FunctionAllergic RhinitisImmunotherapyMedicineAllergic Rhinoconjunctivitis